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Patients with Fabry disease on dialysis in the United States. Fabry disease, an X-linked deficiency of lysosomal
Background. Fabry disease results from an X-linked defi- alpha-galactosidase A, is a rare cause of end stage renal
ciency of lysosomal alpha-galactosidase A and is a rare cause disease (ESRD) [1]. A block in the degradation pathwayof end-stage renal disease. Little is known about the character-
of specific cell membrane glycosphingolipids leads to ac-istics of patients with Fabry disease that initiate dialysis in
the United States, although data from Europe suggests these cumulation of the metabolic intermediates globotriao-
individuals have a poor survival. sylceramide and galabiosylceramide in several organs,
Methods. Using the United States Renal Disease System including the heart, nervous system, and kidney. In-
database, we first studied in detail 42 Fabry patients who initi-
deed, the clinical manifestations of Fabry disease re-ated dialysis between April 1995 (following the introduction of
flect the cellular sites of substrate storage and resultantthe new detailed HCFA 2728 form) and July 1998. To examine
crude survival in a larger cohort, 95 Fabry patients were studied organ dysfunction. In the kidney there is mixed glomeru-
who initiated dialysis between 1985 and 1993, similar to the lar and tubular disease marked by proteinuria, hematu-
European Registry. Diabetic and non-diabetic controls matched
ria, and tubular dysfunction [2]. Ultimately, renal diseaseby age, gender, race, year of dialysis initiation, and initial dial-
progresses to end stage requiring dialysis or transplanta-ysis modality were examined for comparison.
Results. During the years 1995 to 1998, the mean age of Fabry tion by the third or fourth decade of life [3]. Other com-
patients that initiated dialysis was 42 years, 83% were Cauca- mon clinical manifestations include angiokeratoma, cor-
sian, and 10% were African American. Despite the X-linked neal dystrophy, and infiltrative cardiac and neurologicinheritance of Fabry disease, 12% of Fabry patients on dialysis
disease [1].were female. At initiation of dialysis mean serum albumin and
creatinine were significantly higher and mean body mass index The X-linked recessive pattern of inheritance accounts
was significantly lower among Fabry patients, but mean glomer- for the differential expression in affected males and fe-
ular filtration rate was similar to controls. Fabry patients tended male carriers [4]. Hemizygous males generate little or
to have a lower three-year survival compared to non-diabetic
no functional enzyme and consequently develop severecontrols, but the results were not significantly different. In a
manifestations. The phenotype in heterozygous femaleslarger cohort of Fabry patients who initiated dialysis between
1985 and 1993, the three-year survival of Fabry patients was ranges from no apparent disease with perhaps corneal
significantly lower than non-diabetic controls: 63% (95% CI, dystrophy, to severe renal, gastrointestinal, cardiovascu-
50 to 75%) versus 74% (95% CI, 67 to 80%; P  0.03).
lar, and cerebrovascular involvement. The variable clini-Conclusion. End-stage renal disease is associated with sig-
cal expression in female carriers likely results from tissuenificant morbidity and mortality among patients with Fabry
disease. Recent evidence that progression of Fabry disease mosaicism due to lyonization, that is, the random inacti-
may be attenuated by enzyme replacement therapy necessitates vation of one of the two X-chromosomes.
increased awareness of Fabry disease and its comorbidities. Among patients with Fabry disease, ESRD is a major
cause of morbidity and is strongly associated with mortality.
Little is known about the characteristics of patients with
Fabry disease that initiate dialysis in the United States.
However, data from the European Registry of Fabry pa-Key words: end-stage renal disease, X-linked inheritance, enzyme re-
placement therapy, lysosomal -galactosidase A. tients that initiated dialysis between 1985 and 1993 suggest
that these individuals have a poor survival [5]. The intro-
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States Renal Disease System (USRDS) database to study included for this detailed analysis. For patients with more
than one HCFA 2728 form in the database, only thepatients with ESRD due to Fabry disease and compared
this group to a matched population of non-diabetic and earliest version was kept in the analysis database.
Data collected on the HCFA 2728 form before 1995diabetic patients on dialysis.
did not contain detailed laboratory and other demo-
graphic information. Nonetheless, crude survival analysis
METHODS
could be performed from these data, and accuracy would
Study population be improved by including a larger cohort of Fabry pa-
tients for survival analysis. Thus, survival of Fabry pa-Two separate cohorts of Fabry patients and controls
were analyzed. To examine demographic and laboratory tients who had initiated dialysis between 1985 and 1993
was compared to survival of a matched group of diabeticdata in detail, the first cohort consisted of Fabry patients
and matched (age, gender, race, year of dialysis initia- and non-diabetic controls.
tion, initial ESRD treatment modality, and ESRD net-
Statistical analysiswork) controls who had initiated dialysis between 1995
(after the introduction of the new detailed HCFA 2728 Among patients in the primary cohort, several vari-
ables were examined. Race was categorized as Cauca-form) and 1998. Because Fabry disease is a rare disease,
however, a second cohort of Fabry patients and controls sian, African American, and other. Dialysis modality was
defined as the anticipated long-term primary type ofwho initiated dialysis between 1985 and 1993 to examine
crude survival also were studied. The time period of the dialysis at the start of ESRD, and was classified as hemo-
dialysis (HD), continuous ambulatory peritoneal dialysissecond cohort was chosen specifically to compare survival
of Fabry patients in the United States to a similar cohort (CAPD), continuous cycling peritoneal dialysis (CCPD),
and preemptive transplant. Patients were considered toof patients studied in Europe [5]. Patients with a HCFA
2727 or 2727A code as the cause of ESRD were identified have diabetes mellitus if diabetic nephropathy was re-
as having Fabry disease, and each Fabry patient was corded as the cause of ESRD. Hypoalbuminemia was de-
matched to approximately three diabetic and three non- fined as serum albumin below 3.5 g/dL, and severe ane-
diabetic controls. mia was defined as hematocrit below 30%. Glomerular
filtration rate (GFR; measured in mL/min/1.73 m2) was
Data collection estimated using the equation developed by the Modifi-
Data were obtained from the Medical Evidence (Med- cation of Diet in Renal Disease (MDRD) Study Group,
evid), Patient and Treatment History, and Standard which factors in age, gender, race, serum creatinine,
Analysis Files of the USRDS. The Medevid file contains BUN, and serum albumin [7]. Body mass index (BMI;
all data from the new version of the USRD Medical Evi- measured in kg/m2) was estimated with the formula:
dence Form, which is also known as the HCFA 2728 Form, BMI  weight/height2.
implemented in April 1995. This form is completed by Continuous variables were compared with the Student
dialysis units or transplant centers on all patients begin- t test and categorical variables with the chi-square or
ning or returning to ESRD treatment (dialysis or trans- Fisher’s exact test. For each patient, the time until death
plantation) in the United States, whether they are cov- or last date the person was confirmed alive was used to
ered by Medicare (about 92% of all new ESRD patients), plot Kaplan-Meier curves of patient survival. Patients
another type of insurance, or are uninsured [6]. The were censored at the time of transplantation. Survival
Patient File contains information on mortality and causes analysis was performed on both cohorts of patients. The
of death and can be linked to the Medevid file using the survival distribution functions between the Fabry pa-
unique USRDS identification number for each patient. tients and each of the control groups were compared
The new version of the HCFA 2728 form contains using the Log-Rank test, and 95% confidence intervals
demographic data, cause of ESRD, co-morbidity, func- (95% CI) for survival estimates were calculated. Statisti-
tional status, initial ESRD treatment modality, pre- cal analyses were performed using the SAS system for
ESRD use of erythropoietin (rHuEPO), and laboratory Windows version 8.0 (SAS Institute Inc., Cary, NC,
information. The laboratory values, which must be ob- USA) and SPSS for Windows version 8.0 (SPSS Inc.,
tained within 45 days prior to the initiation of dialysis, Chicago, IL, USA).
include hematocrit, hemoglobin, serum albumin, blood
urea nitrogen (BUN), and serum creatinine.
RESULTSThe study subjects in the first cohort consisted of all
Of a total of 250,352 HCFA 2728 forms available inpatients available in the March 1999 update of the Med-
the March 1999 update of the Medevid file, 44 had aevid file. Since the new version of the HCFA 2728 form
HCFA 2727 or 2727A code for Fabry disease as thewas introduced in April 1995, only patients who started
renal replacement therapy at or after that date were cause of ESRD. Two forms were excluded because they
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Table 1. Demographic characteristics of 42 patients with higher among patients with Fabry disease than in non-
Fabry disease as the cause of end-stage renal disease (ESRD)
Fabry controls. However, the proportion of patients withand the overall U.S. ESRD incident population
hypoalbuminemia was not significantly different in both
Fabry disease Overall ESRDa groups. Likewise, no significant differences were observedN  42 N  250,352
in glomerular filtration rate at the initiation of dialysis.
Mean age years 42 61
Mortality was initially ascertained in 41 of the 42 pa-Gender
Male 88% 53% tients with Fabry disease that had initiated dialysis be-
Female 12% 47% tween 1995 and 1998. The overall three-year survival of
Race
Fabry patients was 70% (95% CI, 43 to 97%), comparedCaucasian 83% 63%
African American 10% 30% to 76% (95% CI, 62 to 90%) among non-diabetic controls
Other 7% 7% (P  0.95) and 40% (95% CI, 7 to 73%) among diabetic
Ethnicity
controls (P 0.07). Three patients with Fabry disease diedNon-Hispanic 88% 89%
Hispanic 12% 11% of an unknown cause at 6, 10, and 29 months of follow-
up. One patient died of cardiomyopathy at 2 months anda Data obtained from the 2000 USRDS Annual Data Report
another one of cardiac arrest at 30 months of follow-up.
By three years, 83% of the Fabry patients and 82% of
non-diabetic controls had undergone renal transplanta-
were duplicates for the same patient. Thus, the primary tion, compared with 77% of the diabetic controls.
cohort consisted of 42 patients who began renal replace- Survival was then estimated using a larger database
ment therapy between April 1, 1995 and July 23, 1998. of Fabry patients (N  95) and matched controls (N 
The number of new patients with ESRD due to Fabry 256 non-diabetic and N 240 diabetic) who had initiated
disease in 1995 (April to December), 1996, 1997, and dialysis during the years 1985 to 1993 (Fig. 1). The mean
1998 (January to July) was 8, 17, 13, and 4, respectively. age of Fabry patients was 41 years (SD  9 years). The
Table 1 shows the demographic characteristics of the mean age of males was 39 years (SD 9 years). At three
patients in the primary cohort and the comparison with years, survival was 63% (95% CI, 50% to 75%) for Fabry
the overall U.S. ESRD population. Patients with Fabry patients, compared with 74% (95% CI, 67% to 80%)
disease were younger and more likely to be male and for non-diabetic controls (P  0.03) and 53% (95% CI,
Caucasian than the overall U.S. ESRD incident popula- 46 to 61%) for diabetic controls (P 0.01). The survival
tion. The majority of the patients (74%) were 44 years curves for Fabry patients and non-diabetic controls be-
of age or younger. There were five women in this cohort gan to diverge after approximately 1.5 years. Among the
whose ages ranged from 20 to 68 years. Fabry patients, 42% had undergone a renal transplanta-
Among patients with Fabry disease, the initial renal tion by three years, compared to 29% of non-diabetic
replacement therapy was hemodialysis in 64%, CAPD and 13% of diabetic controls.
in 22% and CCPD in 12%. One patient received a pre-
emptive transplant, and two additional patients received
DISCUSSIONa transplant one and two months after an initial course
of hemodialysis. Pre-dialysis comorbid conditions and Fabry disease is a rare X-linked genetic disorder with
an estimated frequency ranging from 1 in 40,000 to 1laboratory values are presented in Table 2. With regard
to co-morbid conditions, the proportion of patients with in 117,000 [8, 9] and whose major morbidity is ESRD.
Although little is known about patients with Fabry dis-congestive heart failure, peripheral vascular disease, and
hypertension at initiation of renal replacement therapy ease on dialysis, the USRDS provides information among
virtually all patients who initiate dialysis in the Unitedwas lower among patients with Fabry disease compared
to controls (P  0.05). Differences in other co-morbid States, and thus provides information on likely the largest
cohort of U.S. dialysis patients with Fabry disease. Re-conditions did not reach statistical significance, with the
exception of pericarditis and tobacco abuse that were sults of our study show that young male Caucasians make
up the majority of those receiving dialysis due to Fabryborderline significant. Mean body mass index was sig-
nificantly lower among patients with Fabry disease com- disease, and that these individuals do poorly on dialysis.
The male preponderance is due to the X-linked recessivepared to non-Fabry patients.
With regard to pre-dialysis laboratory values, the mean inheritance of Fabry disease. Importantly, women with
Fabry disease comprised approximately 12% of this co-hematocrit was similar in both groups. Compared with
non-Fabry patients, patients with Fabry disease were less hort, and 10% of patients were African American.
Kidney involvement among patients with Fabry dis-likely to receive pre-dialysis rHuEPO (P 0.05), but this
difference did not reach statistical significance among ease is notable for diffuse deposition of glycosphingolipid
in the renal glomeruli, tubules, and vasculature [10, 11].patients with hematocrit of less than 30%. The mean
serum albumin and serum creatinine was significantly Under the light microscope the kidney has a “foamy”
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Table 2. Clinical characteristics of ESRD patients with and without Fabry disease (1995–1998)
Non-Fabry
Fabry All controls Diabetic Non-diabetic
N42 N257 N127 N130
Comorbidity at initiation
Congestive heart failurea 2% 16% 22% 9%
Ischemic heart diseaseb 5% 12% 16% 8%
Myocardial infarctionb 2% 5% 5% 4%
Cardiac arrestb 0% 0% 0% 0%
Arrhythmiab 5% 2% 3% 1%
Pericarditisc 5% 1% 0% 1%
Cerebrovascular diseaseb 2% 3% 5% 1%
Peripheral vascular diseasea 0% 9% 16% 2%
Hypertensiona 52% 71% 75% 68%
Cancerb 2% 1% 1% 1%
COPDb 5% 2% 3% 0%
Tobacco abusec 0% 9% 10% 8%
Alcohol dependenceb 2% 0% 0% 0%
Drug dependenceb 2% 1% 2% 1%
Pre-dialysis laboratory values
Mean serum albumina g/dL 3.60.7 3.20.6 3.10.6 3.40.6
Serum albuminb 3.5 g/dL 42% 57% 65% 49%
Mean hematocritb % 29.46.0 28.56.0 28.25.3 28.76.7
Hematocritb 30% 50% 61% 65% 57%
Mean serum creatininea mg/dL 11.86.3 9.64.2 8.53.4 10.74.6
Mean GFRb,d ml/min/1.73 m2 6.12.4 7.33.5 8.13.7 6.42.9
Pre-dialysis rHuEPO use
Overalla 7% 21% 21% 21%
Among patients with hematocrit 30%b 5% 18% 14% 23%
Body mass indexa kg/m2 23.54.3 26.66.7 25.85.5 27.47.6
Abbreviations are: COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; rHuEPO, erythropoietin.
a P  0.05 for the comparison between Fabry and all non-Fabry patients
b P  0.05 for the comparison between Fabry and all non-Fabry patients
c P  0.053 for pericarditis and 0.055 for tobacco abuse
d Data for GFR calculation was available in only 23 (55%) and 193 (75%) of the Fabry and non-Fabry patients, respectively
Fig. 1. Survival analysis of patients with Fabry
disease and diabetic and nondiabetic controls
from 1985 to 1993.
appearance with diffuse swelling and vacuolization of teinuria, which is rarely in the nephrotic range, and lipid-
uria [12]. Lipiduria, marked by Maltese crosses seen withvisceral podocytes, and electron microscopy studies have
shown that podocytes and mesangial cells are filled with polarized light, found in association with only modest
proteinuria can be a clue to the diagnosis of Fabry diseaselysosomal electron dense granules arranged in lamellar,
myelin-like patterns. Clinically, renal disease manifests [11, 13]. Additionally, concentrating defects and nephro-
genic diabetes insipidus [12, 14], distal renal tubular aci-with hypertension, microscopic hematuria, moderate pro-
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Table 3. Comparison of Fabry patients from the USRDS
and the EDTA-ERA Registries
USRDS EDTA-ERA
N42 N83
Prevalence % 42/250,352 (0.0167%) 83/440,665 (0.0188%)
Mean age years 42 38
Gender
Male 37 (88%) 72 (87%)
Female 5 (12%) 10 (12%)
Initial RRT
Hemodialysis 64% 78%
Peritoneal dialysis 34% 18%
Transplant 2% 1%
RRT is renal replacement therapy.
Fig. 2. Age distribution of Fabry patients at the beginning of renal
replacement. Data are USRDS ( ) versus EDTA-ERA ().
dosis [15], and impaired ammoniagenesis [11] have been
reported. Natural history of renal disease has not been disease [4, 18]. The basis for symptomatic disease in
studied in detail. Historically, uremia was the main cause heterozygous females, beyond lyonization, and the pat-
of mortality among patients with Fabry disease [12]. tern of disease expression and co-morbidities when com-
The prevalence and demographic characteristics of pared to that observed in hemizygous males requires
Fabry patients on dialysis in our study are similar to additional investigation.
those reported in a previous study from the European The prevalence of comorbid conditions in our study
Registry [5]. Using the records of 440,665 patients on was considerably lower than that reported in the Euro-
file in the ERA-EDTA Registry up to December 31, pean Registry study [5]. Based on responses to a mini-
1993, a total of 83 patients were identified as having questionnaire by 42 of the 83 European patients with
ESRD due to Fabry disease. Comparison of characteris- ESRD due to Fabry disease, the prevalence of hyperten-
tics between Fabry patients in both registries is presented sion, cardiovascular complications, congestive heart fail-
in Table 3. Although these were obviously patients from ure or arrhythmia, cerebrovascular accident, angina,
different geographic regions, the prevalence of patients claudication, and myocardial infarction was 79%, 74%,
with Fabry disease on dialysis was strikingly similar be- 33%, 24%, 19%, 10% and 5%, respectively. The lower
tween the two registries, as was the gender distribution. prevalence we found may be due to underreporting of
In contrast, patients in the USRDS were more likely to comorbid conditions on the HCFA 2728 form. Indeed,
choose peritoneal dialysis compared to European Fabry Longenecker et al recently reported that the average
patients. The age distribution among Fabry patients in sensitivity of the HCFA 2728 form across 17 comorbid
the two registries was similar, with the majority of pa- conditions was 0.59, but the specificity was very good
tients commencing renal replacement therapy between for hypertension (0.91) and excellent (0.95) for the
35 and 44 years of age (Fig. 2). Therefore, patients with other 16 conditions, suggesting that comorbid conditions
Fabry disease in the two registries had many similarities, are significantly underreported on Form 2728 but diag-
despite the geographic and potentially genetic differ- noses are not falsely attributed to patients [19]. Another
ences between them. reason for the lower prevalence of comorbid conditions
The renal presentation in heterozygous women is in our study is that the HCFA 2728 form only includes
highly variable [1], and in fact, renal abnormalities may comorbidities present prior to or at initiation of renal
be the only manifestation of Fabry disease in these women replacement therapy, whereas the European Registry
[16, 17]. Indeed, the severity of symptoms is thought to study included comorbidities present at any time during
be worst among males, and given the genetic mode of renal replacement therapy. We could not exclude the
transmission and the variability in presentation, Fabry possibility that U.S. Fabry patients with ESRD may have
disease may be overlooked as an etiology of severe renal less comorbid conditions than their European counter-
disease in women. In both the USRDS and the ERA- parts at the initiation of renal replacement therapy.
EDTA, women constituted approximately 12% of all Just prior to dialysis, the mean serum creatinine of
patients with Fabry disease with ESRD. Of note, two of Fabry patients was significantly higher than controls. The
the five women with ESRD in our cohort were over 60 difference in mean serum creatinine was mostly attribut-
years of age, indicating that ESRD can present late in able to the lower creatinine in the diabetic controls, who
the course of Fabry disease among women. Therefore, also displayed a higher mean GFR than Fabry patients.
women may be severely affected and this diagnosis must These findings are not unexpected since dialysis is typi-
cally initiated earlier in diabetic patients. We were ex-be considered in women with unexplained chronic renal
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pecting that the elevated serum creatinine among Fabry latter would be important to determine because after a
few years on dialysis, the survival curve of Fabry patientspatients would be accompanied by an elevated body
mass index among these individuals. The mean body quickly diverges from the survival curve of non-diabetic
controls. Renal transplantation is another alternative.mass index among Fabry patients, however, was lower
than both non-diabetic and diabetic controls. The sig- Although studies addressing the outcome of Fabry pa-
tients who undergo renal transplantation have been con-nificance of a lower mean body mass among patients
with Fabry disease is not certain. Because gastrointesti- flicting [25], Ojo et al recently demonstrated that patients
with Fabry disease have equivalent five-year patient andnal manifestations of Fabry disease include postprandial
indigestion, nausea, cramps, reflux, and diarrhea [20, 21], graft survival compared to matched controls [25]. In fact,
three-year patient survival was 90%, and graft survivalthese may contribute to the lower body mass index we
observed. In addition, most patients with Fabry disease was 80%. Indeed, transplantation rates between our two
cohorts suggest that a greater proportion of Fabry pa-show progressive disease as a consequence of the build
up of partially degraded substrate derived from normal tients are undergoing renal transplantation now com-
pared to a decade ago. Thus, at this time, renal trans-cellular turnover. One may hypothesize that with in-
creasing age, patients with Fabry disease develop in- plantation should be recommended for eligible Fabry
patients either before or within a few years followingcreased disease burden, and that this progressive burden
may be reflected by the lower mean body mass. Thus, initiation of dialysis. Whether enzyme replacement ther-
apy alters morbidity and mortality while on dialysis orit is plausible that Fabry disease, like other lysosomal
storage diseases, is associated with an increased basal following renal transplantation has yet to be determined,
but early results of recent trials that address progressionmetabolic rate, and that energy expenditure is associated
with the burden of disease [22]. of renal disease are encouraging.
We relied on the HCFA 2728 form to ascertain pa-In our primary cohort of Fabry patients from 1995 to
1998, survival was slightly but not significantly lower than tients with Fabry disease. Although we did not have
access to data that detail how patients were diagnosed,the survival of non-diabetic controls. Only five patients
in our primary cohort died, three of unknown causes given that Fabry disease is an uncommon genetic disor-
der that requires enzymatic or genetic confirmation, theand two of cardiovascular complications. Because of the
limited sample size of this survival analysis (consistent false positive rate is likely to be low. On the other hand,
primarily because of lack of awareness and likely infre-with the wide confidence intervals), we performed addi-
tional survival estimates among a second cohort of Fabry quent testing for rare genetic disorders, we have proba-
bly underestimated the total number of patients withpatients and controls that initiated dialysis between 1985
and 1993. These data demonstrated that the three-year Fabry disease in the USRDS cohort. It is likely that
nephrologists do not commonly consider Fabry diseasesurvival among U.S. Fabry patients (63%) was similar
to the three-year survival estimate reported from the when presented with hypertension and progressive renal
disease in a young man, and it may never be consideredEuropean Registry (60%) [5], and that Fabry patients
in the U.S. had a significantly lower survival compared in a woman. A recent report described a prevalence of
0.8 percent (2 of 254 Japanese hemodialysis patients withto non-diabetic controls. Importantly, non-diabetic con-
trols had a similar three-year survival in both European unknown etiologies of renal failure) of Fabry disease in
an ESRD population based on alpha-galactosidase Aand U.S. cohorts. Our survival data (and those from the
European Registry) are in contrast to those reported by gene mutations consistent with this diagnosis (abstract;
Muto et al, J Am Soc Nephrol 11:411A, 2000). This sug-Nissenson and Port, who studied 17 U.S. Fabry patients
beginning renal replacement therapy (dialysis or trans- gests that the true prevalence of Fabry disease may be
much higher in North America than is appreciated andplantation) between 1983 and 1985 and found a survival
of 83% at three years [18]. The primary difference be- could account for some of the 4% of ESRD patients
who have no clear etiology determined [26].tween our data (and the European data) and those from
Nissenson and Port was that our data were censored at One important limitation of this study is that we did
not include hospitalization data, which would have pro-the time of transplantation.
Given the poor survival of Fabry patients on dialysis, vided information on comorbidities. Hospitalization data
in the USRDS are recorded for patients whose care isone must consider alternative strategies to manage these
patients. Recent trials suggest both renal histological paid for primarily by Medicare. Because the majority of
Fabry patients (65%) were covered by private insur-[23, 24] and functional [24] improvement with enzyme
replacement therapy. Although encouraging, longer fol- ance, data on hospitalizations and admissions were not
available for the majority of patients in cohort 1 (1995low-up is needed to determine whether such therapy will
alter progression to ESRD, lower morbidity on dialysis, to 1998). Furthermore, since hospitalization data were
largely unavailable among patients before 1989, hospital-or perhaps even alter cardiovascular associated morbidi-
ties and overall mortality after initiation of dialysis. The ization data of patients in cohort 2 (1985 to 1993) were
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replacement therapy in the ERA-EDTA Registry. Nephrol Dialincomplete. Although certainly important to examine
Transplant 11:4–20, 1996
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Am J Med 55:415–425, 1973
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